Login
Companies $SGMT
$10.33 +$0.20 (1.97%) After hours
Sagimet Biosciences Inc. logo

Sagimet Biosciences Inc.

Compare classes
sagimet.com

What Do They Do?

Develops fatty acid synthase inhibitor drug candidates for people with MASH, acne and select cancers.

Who Are Their Customers?

Sagimet focuses on discovering and developing drug candidates and has no sales, marketing or distribution capabilities for approved drugs. In Greater China, Ascletis holds a license to develop, manufacture and commercialize denifanstat; Sagimet intends either to build its own commercial organization or outsource the work if a drug is approved.

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Net income
▼ −48% (Loss)
vs −$12.9M in Q3 FY2025
  • Nov 12, 2026 Sagimet began a U.S. Phase 3 acne trial of denifanstat The AURORA trial began dosing its first patient, with topline data expected in the second half of 2027.
  • Sep 30, 2026 Sagimet agreed to sell shares and pre-funded warrants
  • Aug 13, 2026 FDA cleared the Phase 3 denifanstat acne trial

Who Do They Compete With?

Competes with Madrigal Pharmaceuticals, Novo Nordisk, Altimmune, AstraZeneca, Boehringer Ingelheim, Zealand Pharma, Eli Lilly and, Galmed Pharmaceuticals, Gilead Sciences, GSK, Inventiva, Merck &, Pfizer, Roche Holdings, Terns Pharmaceuticals, Viking Therapeutics, and Zydus Therapeutics

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support